F

    Femasys Inc (FEMY)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $3.43
    +0.23 (+7.19%)

    Market Cap: $26.80M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(12/21)
    Avg Surprise
    +1.03%
    Streak
    5 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.60
    Range$-0.68 - $-0.52
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-1.50-150.0%
    60d ago$-1.50-150.0%
    30d ago$-1.50-150.0%
    7d ago$-1.50-150.0%
    Current$-0.60
    Revenue Consensus
    $690000
    Range$580000 - $800000
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.48
    Range$-0.94 - $-0.02
    2 analysts
    Revenue Consensus
    $184330
    Range$56330 - $312330
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.48---
    Sep 26EST
    		-$-0.60---
    Jun 26
    		$-1.33$-1.40+5.00%Beat+58.4%
    Mar 26
    		$-1.46$-1.80+18.89%Beat-534.8%
    Dec 25
    		$-0.20N/A+88.89%Beat+95.7%
    Sep 25
    		$-2.00$-2.60+23.08%Beat+58.3%
    Jun 25
    		$-3.20$-3.60+11.11%Beat+23.8%
    Mar 25
    		$-0.23$-0.19-21.05%Miss+93.2%
    Dec 24
    		$-4.60$-3.80-21.05%Miss-2321.1%
    Sep 24
    		$-4.80$-3.93-22.14%Miss+7.7%
    Jun 24
    		$-4.20$-3.47-21.04%Miss+4.5%
    Mar 24
    		$-3.40$-4.10+17.07%Beat-1260.0%
    Dec 23
    		$-0.19$-0.21+9.52%Beat+96.0%
    Sep 23
    		$-5.20$-5.00-4.00%Miss-4.0%
    Jun 23
    		$-4.40$-4.40+0.00%Beat+0.0%
    Mar 23
    		$-0.25$-0.26+3.85%Beat+94.8%
    Dec 22
    		$-4.80$-5.20+7.69%Beat-5900.0%
    Sep 22
    		$-5.00$-4.60-8.70%Miss-2531.6%
    Jun 22
    		$-4.40$-5.20+15.38%Beat-746.2%
    Mar 22
    		$-4.80$-4.20-14.29%Miss-1746.2%
    Dec 21
    		$-0.08N/A+68.00%Beat+90.0%
    Sep 21
    		$-0.19$-0.15-26.67%Miss+88.4%
    Jun 21
    		$-0.52$-0.25-108.00%Miss+66.6%
    Mar 21
    		$-0.26$0.00N/AMiss+88.7%
    Dec 20
    		$-0.80$0.00N/AMiss-
    Jun 20
    		$-1.64$0.00N/AMiss-
    Mar 20
    		$-1.55$0.00N/AMiss-
    Dec 19
    		$-2.30$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.69EV/EBITDA0.24x
    Price/FCF-0.64xFCF Yield-156.97%
    Profitability
    Profit Margin0.00%Operating Margin-1527.00%
    ROE-425.00%ROIC-154.02%
    Financial Health
    Debt/Equity0.87xInterest Coverage-8.93x
    Current Ratio2.14xQuick Ratio0.55x
    Trading Statistics
    Beta-2.09Avg Volume2.05M
    52-Week High$22.2052-Week Low$2.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.88
    SMA 20$2.71
    SMA 50$3.24
    SMA 200$9.04
    EMA 10$2.94
    EMA 20$2.90
    EMA 50$3.56
    EMA 200$8.20

    MACD

    Line: -0.06Signal: -0.21Hist: 0.15

    ADX

    ADX: 25.9+DI: 24.4-DI: 11.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down60.0
    PSAR$2.27

    Bollinger Bands

    Upper Band$3.44
    Lower Band$1.98
    %B Position5371%(Upper)
    Band Width0.99

    RSI (14-Day)

    Neutral
    59.9

    Momentum Oscillators

    Stoch %K67.0
    Stoch %D57.9
    Williams %R-15.6
    ROC (10d)58.8%
    Momentum1.27
    CCI (20d)134.9
    MFI (14d)94.5

    Volatility Measures

    ATR (14d)$0.48(14.1%)
    StdDev (20d)0.36
    Hist Vol124.7%(High)

    Volume Flow

    VWAP$3.32
    OBV302.0M
    AD Line164.8B
    CMF (20d)-0.322

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio0.1x(Low)
    VWMA (20d)$2.71

    Pivot Points

    R3$4.06
    R2$3.71
    R1$3.45
    Pivot Point$3.10
    S1$2.84
    S2$2.49
    S3$2.23

    Advanced Oscillators

    TSI-5.41
    Ultimate Osc54.2
    KST-114.44

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$331,827$424,889$813,387$729,394$409,268$341,264$581,576$554,908$221,484$271,140$213,111$244,361
    Cost of Revenue$142,436$158,606$303,125$293,838$158,171$117,266$192,407$190,839$73,125$88,532$78,294$86,186
    Gross Profit$189,391$266,283$510,262$435,556$251,097$223,998$389,169$364,069$148,359$182,608$134,817$158,175
    Operating Expenses$5.26M$4.49M$5.13M$4.09M$4.10M$5.68M$5.11M$5.48M$4.63M$3.65M$4.58M$4.24M
    R&D$1.95M$1.31M$1.81M$1.38M$1.41M$2.97M$2.17M$2.30M$1.98M$1.77M$2.07M$2.07M
    SG&A$1.93M$1.78M$1.83M$1.48M$1.62M$1.72M$1.68M$1.53M$1.61M$1.50M$2.22M$1.97M
    Operating Income$-5,065,874$-4,223,533$-4,622,728$-3,653,768$-3,851,566$-5,460,607$-4,722,572$-5,118,440$-4,482,151$-3,462,642$-4,449,515$-4,081,264
    Interest Income$19,694$49,827$48,272$17,315$17,144$19,029$49,504$124,028$184,138$224,684$198,886$92,392
    Interest Expense$186,050$176,607$408,097$532,073$491,500$459,449$440,422$413,290$388,311$361,552$0$8,033
    Income Before Tax$-4,468,230$846,100$-3,944,820$-4,194,821$-4,585,922$-5,901,027$-5,113,490$-5,407,702$-4,686,324$-3,599,510$-4,406,116$-3,996,905
    Income Tax Expense$865$0$5,485$0$0$-4,188$10,194$1,158$-1,750$0$0$0
    Net Income$-4,469,095$846,100$-3,950,305$-4,194,821$-4,585,922$-5,896,839$-5,123,684$-5,408,860$-4,684,574$-3,599,510$-4,410,454$-3,996,905
    EBITDA$-3,918,418$1.35M$-4,201,408$-3,042,446$-3,506,756$-4,886,848$-4,166,645$-4,592,183$-3,982,455$-2,979,948$-4,099,408$-3,830,329
    EBIT$-4,301,874$972,880$-4,622,728$-3,680,063$-4,111,566$-5,460,607$-4,722,572$-5,118,440$-4,482,151$-3,462,642$-4,449,515$-4,081,264
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FEMY

    News

    Biotech Femasys (NASDAQ: FEMY) raises $30M in private round

    Femasys (NASDAQ: FEMY), a Delaware biotechnology corporation, announced a private securities offering, raising $30 million. The offering of equity and options was fully subscribed, with the first sale reported on August 10, 2026, and relied on a Regulation D exempt offering under Rule 506(b). The company declined to disclose its revenue range, and the filing did not specify the use of proceeds or potential dilution.

    Stock Titan•8/20/26•
    Somewhat-Bullish

    Femasys Secures FDA Pathway for Non-Surgical Contraceptive

    Femasys, Inc. announced that the FDA has authorized the modular premarket approval application pathway for FemBloc, its non-surgical permanent birth control technology, which is designed for in-office delivery and avoids surgery and anesthesia. Despite this regulatory milestone, Femasys' stock is in a bearish trend, with significant declines over the past year, though it saw a 24.09% increase at the time of publication on Wednesday.

    Sahm•8/20/26•
    Somewhat-Bullish

    Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control

    Femasys Inc. shares rose after the FDA authorized a modular premarket approval pathway for FemBloc, its non-surgical permanent birth control technology. This pathway allows Femasys to submit parts of its application while clinical trials continue, aiming to accelerate U.S. approval for the device, which is already approved in Europe, the U.K., and New Zealand. The company recently raised $30 million to fund its U.S. clinical program, and its stock saw an intraday rally before settling higher.

    BigGo Finance•8/19/26•
    Bullish

    Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc

    Femasys has received FDA approval for a modular premarket approval (PMA) pathway for FemBloc, its non-surgical permanent birth control technology. This approval allows Femasys to submit portions of its regulatory application for review while the pivotal U.S. clinical trial, FINALE, is still ongoing. The company plans to leverage its existing commercial team for fertility products to support FemBloc's potential U.S. launch, following its previous regulatory approvals in Europe, the UK, and New Zealand.

    Yahoo Finance•8/19/26•
    Bullish

    Femasys receives FDA approval for modular PMA pathway for FemBloc

    Femasys Inc. announced that the FDA has approved a modular premarket approval (PMA) pathway for its investigational non-surgical permanent birth control technology, FemBloc. This approval allows for early FDA review of key components of the submission, accelerating its path to U.S. market. FemBloc is already approved in Europe, the UK, and New Zealand since 2025 and uses a patented delivery system that forms scar tissue for permanent occlusion without anesthesia or incisions.

    Investing.com•8/19/26•
    Bullish

    Frequently Asked Questions About FEMY

    Does FEMY pay dividends?
    Femasys Inc (FEMY) does not currently pay a regular dividend.
    What is FEMY's market cap?
    Femasys Inc (FEMY) has a market capitalization of $26.80M with a current stock price of $3.43.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In